News
March 23, 2023
BriSTAR Immunotech to Present its Novel Cell Therapy for Acute Myeloid Leukemia at the 2023 AACR Annual Meeting
March 23, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy platform at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.
Poster Presentation Details:
Title: Development of LILRB4 biparatopic synthetic T-cell receptor and antigen receptor (STAR)-T cells for the treatment of acute myeloid leukemia (AML)
Session Category: Clinical Research Excluding Trials
Session Title: Adoptive Cell Therapy 2
Session Date and Time: Monday Apr 17, 2023 1:30 PM - 5:00 PM ET
Published Abstract Number: 3185
Abstract link：https://www.abstractsonline.com/pp8/#!/10828/presentation/3051
The complete abstract will be available here. An electronic copy of the poster is available upon request EMAIL: info@bristarimmunotech.com.
BriSTAR Immunotech has developed LILRB4 STAR-T cell therapy for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML). This novel cell therapy drug candidate was developed using BriSTAR’s STAR-T platform to introduce the biparatopic STAR gene targeting LILRB4 into autologous T cells with a lentiviral gene transduction approach. This next generation T cell therapy uses two novel nano-antibodies that bind to different epitopes and fuse to the alpha and beta chains of the STAR structure, respectively. This gives LILRB4 STAR-T better antigen engagement and increased cytotoxicity against this highly aggressive AML. In December 2022, the LILRB4 STAR-T program received Orphan Drug Designation from the U.S. FDA, and exploratory clinical studies are underway in China.
About Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) occurs when the bone marrow cells develop genetic abnormalities. It is one of the most common hematopoietic cancers, with an incidence of over 20,000 cases per year in the United States, and 13,200 cases per year in China.
Patients with AML have limited treatment options. Even the current chimeric antigen receptor (CAR)-T therapy has limited efficacy due to the heterogeneity of AML cells and lack of leukemic cell-specific targets. The LILRB4 immunosuppressive receptor (also known as ILT3, CD85k) shows potential to be an ideal therapeutic target for monocytic AML because it is highly expressed on monocyte AML blasts (FAB M4 and M5 AML subtypes).
About STAR-T Platform
BriSTAR Immunotech’s Synthetic TCR and Antigen Receptor (STAR)-T Platform is highly effective at building a cell therapy pipeline for treating hematological and solid tumors. The STAR-T platform offers a natural framework for engineering dual-targeting T cell therapy products that provide sensitive target engagement and strong tumor infiltration.
About BriSTAR Immunotech
Founded in 2018, BriSTAR Immunotech Limited is a clinical stage company focused on developing better T cell therapies for the treatment of cancer and viral infections. The Company’s proprietary STAR-T platform, like CAR-T, is HLA-independent, but also uses the full TCR-signaling complex to engage and kill cancer cells. BriSTAR’s pipeline includes product candidates indicated for AML and solid tumors, as well as viral infections. The Company’s lead product, CD19/CD20 STAR-T, is a dual targeting cell therapy candidate. CD19/CD20 STAR-T is currently in clinical trials for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).
Poster Presentation Details:
Title: Development of LILRB4 biparatopic synthetic T-cell receptor and antigen receptor (STAR)-T cells for the treatment of acute myeloid leukemia (AML)
Session Category: Clinical Research Excluding Trials
Session Title: Adoptive Cell Therapy 2
Session Date and Time: Monday Apr 17, 2023 1:30 PM - 5:00 PM ET
Published Abstract Number: 3185
Abstract link：https://www.abstractsonline.com/pp8/#!/10828/presentation/3051
The complete abstract will be available here. An electronic copy of the poster is available upon request EMAIL: info@bristarimmunotech.com.
BriSTAR Immunotech has developed LILRB4 STAR-T cell therapy for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML). This novel cell therapy drug candidate was developed using BriSTAR’s STAR-T platform to introduce the biparatopic STAR gene targeting LILRB4 into autologous T cells with a lentiviral gene transduction approach. This next generation T cell therapy uses two novel nano-antibodies that bind to different epitopes and fuse to the alpha and beta chains of the STAR structure, respectively. This gives LILRB4 STAR-T better antigen engagement and increased cytotoxicity against this highly aggressive AML. In December 2022, the LILRB4 STAR-T program received Orphan Drug Designation from the U.S. FDA, and exploratory clinical studies are underway in China.
About Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) occurs when the bone marrow cells develop genetic abnormalities. It is one of the most common hematopoietic cancers, with an incidence of over 20,000 cases per year in the United States, and 13,200 cases per year in China.
Patients with AML have limited treatment options. Even the current chimeric antigen receptor (CAR)-T therapy has limited efficacy due to the heterogeneity of AML cells and lack of leukemic cell-specific targets. The LILRB4 immunosuppressive receptor (also known as ILT3, CD85k) shows potential to be an ideal therapeutic target for monocytic AML because it is highly expressed on monocyte AML blasts (FAB M4 and M5 AML subtypes).
About STAR-T Platform
BriSTAR Immunotech’s Synthetic TCR and Antigen Receptor (STAR)-T Platform is highly effective at building a cell therapy pipeline for treating hematological and solid tumors. The STAR-T platform offers a natural framework for engineering dual-targeting T cell therapy products that provide sensitive target engagement and strong tumor infiltration.
About BriSTAR Immunotech
Founded in 2018, BriSTAR Immunotech Limited is a clinical stage company focused on developing better T cell therapies for the treatment of cancer and viral infections. The Company’s proprietary STAR-T platform, like CAR-T, is HLA-independent, but also uses the full TCR-signaling complex to engage and kill cancer cells. BriSTAR’s pipeline includes product candidates indicated for AML and solid tumors, as well as viral infections. The Company’s lead product, CD19/CD20 STAR-T, is a dual targeting cell therapy candidate. CD19/CD20 STAR-T is currently in clinical trials for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).
Previous chapter：Already the First Article
Next article：BriSTAR Immunotech to Present at the BIO CEO & Investor Conference